CAS: 114-80-7; 3-((Dimethylcarbamoyl)Oxy)-N,N,N-Trimethylbenzenaminium Bromide

上下游产品

methyl bromide norneostigmine 3-Dimethylaminophenol N,N-dimethylcarbamoyl bromidedimethyl amine Dimethylcarbaminsaeure-3-aminophenylester norneostigmine Dimethylcarbaminsaeure-3-methylaminophenylester

3-羟基-N,N-二甲基苯胺 反应生成溴化新斯的明
参考文献:Ch208883
标题:Ch208883

专利信息

专利号:US-9315483-B2
优先权日:2007-09-13
标题 :Synthesis of deuterated catechols and benzo[D][1,3]dioxoles and derivatives thereof
发明人：JONES ANDREW D; ZELLE ROBERT E; SILVERMAN I ROBERT
权利人:CONCERT PHARMACEUTICALS INC
摘要:The present invention provides a convenient and efficient process for the synthesis of d 2 -benzo[d][1,3]dioxoles.

专利号:US-10906888-B2
优先权日:2016-07-14
标 题:Pyrimidine carboxamides as inhibitors of Vanin-1 enzyme
发明人：CASIMIRO-GARCIA AGUSTIN; STROHBACH JOSEPH WALTER; HEPWORTH DAVID; LOVERING FRANK ELDRIDGE; CHOI CHULHO; ALLAIS CHRISTOPHE PHILIPPE; WRIGHT STEPHEN WAYNE
权利人:PFIZER
摘要:Compounds, pharmaceutically acceptable salts thereof, are disclosed wherein the compounds have the structure of (I) as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

专利号:WO-2009035652-A1
优先权日:2007-09-13
标 题 :Synthesis of deuterated catechols and benzo[d][1,3] dioxoles and derivatives thereof

专利号:WO-2011011384-A9
优先权日:2009-07-20
标 题 :Synthesis of dendrimer conjugates

专利号:US-2007117975-A1
优先权日:2005-09-13
标 题 :Processes for the synthesis of rocuronium bromide

专利号:US-9751877-B2
优先权日:2012-09-21
标题 :Substituted pyrido[1,2-a]pyrazines for the treatment of neurodegenerative and neurological disorders
发明人：PETTERSSON MARTIN YOUNGJIN; JOHNSON DOUGLAS SCOTT; SUBRAMANYAM CHAKRAPANI; O'DONNELL CHRISTOPHER JOHN; AM ENDE CHRISTOPHER WILLIAM; GREEN MICHAEL ERIC; PATEL NANDINI CHATURBHAI; STIFF CORY MICHAEL; TRAN TUAN PHONG; KAUFFMAN GREGORY WAYNE; STEPAN ANTONIA FRIEDERIKE; VERHOEST PATRICK ROBERT
权利人:PFIZER
摘要:Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I n nas defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.